Your SlideShare is downloading. ×
Canada Pharmaceuticals and Healthcare Report Q4 2010
Canada Pharmaceuticals and Healthcare Report Q4 2010
Canada Pharmaceuticals and Healthcare Report Q4 2010
Canada Pharmaceuticals and Healthcare Report Q4 2010
Canada Pharmaceuticals and Healthcare Report Q4 2010
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Canada Pharmaceuticals and Healthcare Report Q4 2010

105

Published on

In BMI's Business Environment Ratings (BERs) for Q410, Canada remains in second place in the expanded regional matrix, trailing the US by around eight points. Globally, Canada ranks third of the 83 …

In BMI's Business Environment Ratings (BERs) for Q410, Canada remains in second place in the expanded regional matrix, trailing the US by around eight points. Globally, Canada ranks third of the 83 markets surveyed, after the US and now behind Australia. Despite a tightening cost-containment environment, provincial variations regarding drug approvals and subsidies and the country's appearance on the Priority Watch List in the 2010 submission of Special 301 report, Canada will remain one of the most attractive pharmaceutical markets on a worldwide scale, in part due to its high per-capita spending on medicines, which topped US$629 in 2009, as well as population expansion and ageing. Having been valued at CAD24.2bn (US$21.2bn) at consumer prices in 2009 and accounting for around 12% of the country's GDP, the Canadian pharmaceutical market is forecast to post a compound annual growth rate (CAGR) of 4.34% in local currency terms, reaching CAD29.9bn (US$26.0bn) in value by 2014. Growth over the 2009-2019 period will slow to 3.09%, although in the latter parts of the forecast the patented medicines segment should be boosted by the use of more personalised therapies and novel medicines. Generics, however, will post the strongest five- and ten-year CAGRs, at 8.34% and 6.12% in local currency terms, respectively, to reach CAD14.9bn (US$13.0bn) in 2019 values. However, Canada's healthcare system is facing serious challenges in terms of affordability and accessibility, as well as failing to meet the medical needs of Canada's changing demographics, according to a report released by the Canadian Medical Association (CMA) in August 2010. The country's healthcare system is increasingly being recognised as inadequate for the long-term needs of the population, and extensive reforms are being proposed ahead of the renegotiation of the current Health Accord, which is set to expire on March 31 2014. First Ministers have described the current level of spending on prescription drugs in the National Pharmaceutical Strategy as 'catastrophic', which is expected to lead to some policy changes and further cost-containment initiatives. To this end, the British Columbia government recently announced that the prices of generic drugs covered by PharmaCare are to be reduced to 35% of the price of their branded counterparts. Market growth opportunities for the out-of-pocket segment will, however, remain limited, given the outlook for a modest growth in private consumption levels and the anticipated slowdown in GDP growth over the medium term. Despite having one of the strongest fiscal positions in the developed world, austerity has become the watchword across Canada, with Ottawa and the provinces cutting back spending. In line with a trend that is beginning to prevail across the developed world, Canadian Finance Minister Jim Flaherty reiterated during the G20 meetings in Toronto in June 2010 that the government remains set on eliminating the deficit by 2014 'or so'. In the meantime, as the Canadian consumer has proven extraordinarily resilient despite external headwinds emanating from the United States, we recently upgraded our 2010 real GDP growth forecast for 2010 from 3.1% to 3.3%, though we are still pencilling in a slowdown in 2011 to 2.4%, in line with our global outlook.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
105
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Canada Pharmaceuticals and Healthcare Report Q4 2010Published on September 2010 Report SummaryIn BMIs Business Environment Ratings (BERs) for Q410, Canada remains in second place in the expanded regional matrix, trailingthe US by around eight points. Globally, Canada ranks third of the 83 markets surveyed, after the US and now behind Australia.Despite a tightening cost-containment environment, provincial variations regarding drug approvals and subsidies and the countrysappearance on the Priority Watch List in the 2010 submission of Special 301 report, Canada will remain one of the most attractivepharmaceutical markets on a worldwide scale, in part due to its high per-capita spending on medicines, which topped US$629 in2009, as well as population expansion and ageing.Having been valued at CAD24.2bn (US$21.2bn) at consumer prices in 2009 and accounting for around 12% of the countrys GDP,the Canadian pharmaceutical market is forecast to post a compound annual growth rate (CAGR) of 4.34% in local currency terms,reaching CAD29.9bn (US$26.0bn) in value by 2014. Growth over the 2009-2019 period will slow to 3.09%, although in the latter partsof the forecast the patented medicines segment should be boosted by the use of more personalised therapies and novel medicines.Generics, however, will post the strongest five- and ten-year CAGRs, at 8.34% and 6.12% in local currency terms, respectively, toreach CAD14.9bn (US$13.0bn) in 2019 values.However, Canadas healthcare system is facing serious challenges in terms of affordability and accessibility, as well as failing to meetthe medical needs of Canadas changing demographics, according to a report released by the Canadian Medical Association (CMA)in August 2010. The countrys healthcare system is increasingly being recognised as inadequate for the long-term needs of thepopulation, and extensive reforms are being proposed ahead of the renegotiation of the current Health Accord, which is set to expireon March 31 2014. First Ministers have described the current level of spending on prescription drugs in the National PharmaceuticalStrategy as catastrophic, which is expected to lead to some policy changes and further cost-containment initiatives. To this end, theBritish Columbia government recently announced that the prices of generic drugs covered by PharmaCare are to be reduced to 35%of the price of their branded counterparts.Market growth opportunities for the out-of-pocket segment will, however, remain limited, given the outlook for a modest growth inprivate consumption levels and the anticipated slowdown in GDP growth over the medium term. Despite having one of the strongestfiscal positions in the developed world, austerity has become the watchword across Canada, with Ottawa and the provinces cuttingback spending. In line with a trend that is beginning to prevail across the developed world, Canadian Finance Minister Jim Flahertyreiterated during the G20 meetings in Toronto in June 2010 that the government remains set on eliminating the deficit by 2014 or so.In the meantime, as the Canadian consumer has proven extraordinarily resilient despite external headwinds emanating from theUnited States, we recently upgraded our 2010 real GDP growth forecast for 2010 from 3.1% to 3.3%, though we are still pencilling ina slowdown in 2011 to 2.4%, in line with our global outlook. Table of ContentExecutive Summary 5SWOT Analysis 6Canada Pharmaceuticals And Healthcare Industry SWOT ... 6Canada Political SWOT 7Canada Economic SWOT ..... 7Pharmaceutical Business Environment Ratings .. 8Table: Americas Pharmaceuticals Business Environment Ratings, Q410 ... 8Canada Pharmaceuticals and Healthcare Report Q4 2010 Page 1/5
  2. Find Industry reports, Company profilesReportLinker and Market StatisticsRewards 9Risks ... 10Canada Market Summary ... 11Pharmacovigilance ..... 13Biosimilars .. 15OTC Medicines ... 16Intellectual Property Regime ...... 16International Collaboration 17Pricing Regime ... 19Provincial Pricing Systems . 20Reimbursement Regime ....... 22Recent Pricing and Reimbursement Developments ..... 23Industry Developments. 25Epidemiology ...... 25Healthcare Sector ....... 27International Comparison ... 28Health Expenditure ..... 29Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators .. 30National Pharmaceuticals Strategy .... 31Pharmaceutical Retail 33Research and Development Sector ...... 34Biotechnology ..... 35Medical Devices Industry ... 37Recent Developments in the Medical Devices Industry ....... 38Industry Forecast Scenario ... 40Overall Market Forecast..... 40Key Growth Factors Industry... 42Key Growth Factors Macroeconomic ...... 44Table: Canada Economic Activity .... 47Prescription Drug Market Forecast .... 49Patented Product Market Forecast ..... 50Generic Drug Market Forecast ... 52OTC Medicine Market Forecast . 54Medical Device Market Forecast 56Pharmaceutical Trade Forecasts 57Other Healthcare Data ....... 57Competitive Landscape 58Pharmaceutical Industry ..... 58Pharmaceutical Re-import Policy ....... 58Recent Pharmaceutical Company Developments 60Company Profiles .. 63Indigenous Manufacturers ....... 63Apotex . 63Biovail (Valeant) . 65Leading Multinational Manufacturers ..... 68Pfizer .. 68GlaxoSmithKline . 70Sanofi-Aventis ..... 72Merck and Co ..... 74Novartis ...... 76Canada Pharmaceuticals and Healthcare Report Q4 2010 Page 2/5
  3. Find Industry reports, Company profilesReportLinker and Market StatisticsCountry Snapshot: Canada Demographic Data .. 78Section 1: Population ....... 78Table: Demographic Indicators, 2005-2030 ....... 78Table: Rural/Urban Breakdown, 2005-2030 ...... 79Section 2: Education And Healthcare ...... 79Table: Education, 2000-2003 ..... 79Table: Vital Statistics, 2005-2030 ....... 79Section 3: Labour Market And Spending Power ...... 80Table: Employment Indicators, 2001-2006 . 80Table: Consumer Expenditure, 2000-2012 (US$) ....... 80Table: Average Annual Manufacturing Wages, 2000-2012 81BMI Methodology .. 82How We Generate Our Pharmaceutical Industry Forecasts ....... 82Pharmaceuticals Business Environment Ratings 83Risk/Reward Ratings Methodology ..... 83Ratings Overview 83Table: Pharmaceutical Business Environment Indicators .. 84Weighting .... 85Table: Weighting Of Components ....... 85Sources ....... 85Forecast Tables ..... 86Canada Pharmaceuticals and Healthcare Report Q4 2010 Page 3/5
  4. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Canada Pharmaceuticals and Healthcare Report Q4 2010 Product Formats Please select the product formats and the quantity you require. Digital Copy--USD 530.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Canada Pharmaceuticals and Healthcare Report Q4 2010 Page 4/5
  5. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Canada Pharmaceuticals and Healthcare Report Q4 2010 Page 5/5

×